False positivity of FDG-PET/CT in a child with Hodgkin disease

Pediatr Blood Cancer. 2008 Apr;50(4):881-3. doi: 10.1002/pbc.21197.

Abstract

Role of Positron Emission Tomography (PET) with F-18-2-fluoro-2-deoxy-D-glucose (FDG) in staging of Hodgkin disease is well established despite several controversies. We report a Stage III Hodgkin lymphoma patient with false positive FDG-PET/CT results. Seven-year-old male with Hodgkin lymphoma was in remission at end of chemotherapy. At third and fourth month of postchemotherapy follow-up, increased Gallium uptake and positive FDG-PET/CT in right lower quadrant of abdomen was observed. Open biopsy revealed lymphoid hyperplasia. He has been followed for 21 months without any evidence of disease. Despite its documented benefit, we believe that results of FDG-PET/CT should be interpreted with great caution in order to avoid unnecessary interventions.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Child
  • False Positive Reactions
  • Gallium
  • Glucose-6-Phosphate / analogs & derivatives*
  • Hodgkin Disease / diagnosis*
  • Hodgkin Disease / drug therapy
  • Humans
  • Male
  • Neoplasm Recurrence, Local / diagnosis*
  • Neoplasm Staging
  • Positron-Emission Tomography*
  • Radiopharmaceuticals*
  • Tomography, X-Ray Computed*

Substances

  • Radiopharmaceuticals
  • 2-fluoro-2-deoxyglucose-6-phosphate
  • Glucose-6-Phosphate
  • Gallium